Drug Profile
Lexaptepid pegol
Alternative Names: NOX-H94Latest Information Update: 01 Aug 2022
Price :
$50
*
At a glance
- Originator NOXXON Pharma AG
- Developer TME Pharma
- Class Antianaemics; Oligonucleotides; Polyethylene glycols
- Mechanism of Action Hepcidin inhibitors; Interleukin 6 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Anaemia
Highest Development Phases
- Discontinued Anaemia
Most Recent Events
- 18 Oct 2018 Discontinued - Phase-I for Anaemia (In volunteers) in Netherlands (IV)
- 18 Oct 2018 Discontinued - Phase-I for Anaemia (In volunteers) in United Kingdom (SC)
- 18 Oct 2018 Discontinued - Phase-I/II for Anaemia in Italy, Germany, United Kingdom (IV)